Biopharma & Life Sciences

Editas Medicine Executive Compensation (FY25)

Name: Editas Medicine (EDIT) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

EDIT · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Gilmore O'Neill

Latest say-on-pay support

June 17, 2026

Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.

See every company’s exec pay — free for 3 days, no card See the plan and pricing

The Editas Medicine brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

Data as of November 6, 2026Latest filing (8-K): June 18, 2026

11 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Editas Medicine brief$500Get the executive brief

Velarion Intel, one year, every company

203 figures on this page: 195 cited to the filing that reported them, 8 calculated from figures it prints. See the citations

This company is not required to report a chief executive pay ratio.

What changed from fiscal 2024 to fiscal 2025

The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.

Chief executive total compensation — Gilmore O'Neill: $5,126,868 → $2,353,655 (54.1% lower)

Say-on-pay support: 61.1% → 83.9% (22.8 points higher)

Frequently asked questions

Answers drawn from the data on this page.

Who is Editas Medicine's chief executive and what were they paid?

Gilmore O'Neill, President and Chief Executive Officer, received $2,353,655 in total compensation for fiscal 2025. Compared with the $5,126,868 reported for fiscal 2024, O'Neill's total was 54.1% lower.

What was Editas Medicine's say-on-pay result?

For fiscal 2025, shareholders backed the say-on-pay proposal with 83.9% of votes cast for or against in favor at the meeting held June 17, 2026.

Which companies are in Editas Medicine's peer group?

The disclosed peer group names Adicet Bio, Inc., Cabaletta Bio, Inc., Caribou Biosciences, Inc., Fate Therapeutics, Inc. and Lexeo Therapeutics, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Michelle Robertson Former Executive Vice President and Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Baisong Mei Senior Vice President and Chief Medical Officer	◇	◇	◇	◇	◇	—	◇	◇
Bruce Eaton Former Executive Vice President and Chief Business Officer	◇	◇	◇	◇	◇	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Gilmore O'Neill President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Erick Lucera Former Executive Vice President and Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Michelle Robertson Former Executive Vice President and Chief Financial Officer Departed during or after this year	◇	—	◇	◇	—	—	◇	◇
Linda Burkly Executive Vice President and Chief Scientific Officer	◇	—	◇	◇	◇	—	◇	◇
Bruce Eaton Former Executive Vice President and Chief Business Officer Departed during or after this year	◇	—	◇	◇	◇	—	◇	◇
Baisong Mei Former Executive Vice President and Chief Medical Officer	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Gilmore O'Neill President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Erick Lucera Former Executive Vice President and Chief Financial Officer Departed during or after this year	◇	—	◇	◇	◇	—	◇	◇
Baisong Mei Former Executive Vice President and Chief Medical Officer Departed during or after this year	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Gilmore O'Neill President and Chief Executive Officer	◇	—	—	◇	◇	—	◇	◇
Linda Burkly Executive Vice President and Chief Scientific Officer	◇	—	—	◇	◇	—	◇	◇
Amy Parison Senior Vice President and Chief Financial Officer	◇	—	—	◇	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Amy Parison	OPTION	—	—	—	—	—	—	◇
Gilmore O'Neill	OPTION	—	—	—	—	—	—	◇
Linda Burkly	OPTION	—	—	—	—	—	—	◇

Fiscal 2023 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Gilmore O'Neill	Option	◇	—	◇	3/7/2035
	Option	◇	—	◇	3/1/2034
	Option	◇	—	◇	3/7/2035
	RSU	◇	◇	—	—
	Option	◇	—	◇	6/1/2032
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/1/2033
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Linda Burkly	Option	◇	—	◇	3/7/2035
	Option	◇	—	◇	3/7/2035
	Option	◇	—	◇	7/23/2033
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/1/2034
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Amy Parison	Option	◇	—	◇	3/7/2035
	Option	◇	—	◇	3/7/2035
	Option	◇	—	◇	4/7/2035
	Option	◇	—	◇	3/1/2034
	RSU	◇	◇	—	—
	Option	◇	—	◇	9/8/2032
	Option	◇	—	◇	3/1/2033
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Jessica Hopfield, Ph.D Board chair	◇	—	◇	—	—	—	◇
Andrew Hirsch	◇	—	◇	—	—	—	◇
Bernadette Connaughton	◇	—	◇	—	—	—	◇
Elliott Levy, M.D	◇	—	◇	—	—	—	◇
David T. Scadden, M.D	◇	—	◇	—	—	—	◇

Gilmore O'Neill, M.B., M.M.Sc served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Lead independent director premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Equity is delivered as Stock Options.

Stock ownership guideline: Set robust executive and non-employee director Stock Ownership Guidelines

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

Adicet Bio, Inc. ACET
Cabaletta Bio, Inc. CABA
Caribou Biosciences, Inc. CRBU
Fate Therapeutics, Inc. FATE
Lexeo Therapeutics, Inc. LXEO
Lyell Immunopharma, Inc. LYEL
Neurogene Inc. NGNE
Nkarta, Inc. NKTX
Prime Medicine, Inc. PRME
Solid Biosciences Inc. SLDB
Tenaya Therapeutics, Inc. TNYA
TScan Therapeutics, Inc. TCRX
Voyager, Inc. VYGR

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	June 17, 2026	=	◇	◇	◇
2024	May 29, 2025	=	◇	◇	◇
2023	May 30, 2024	=	◇	◇	◇
2022	June 1, 2023	=	◇	◇	◇
2021	June 9, 2022	=	◇	◇	◇
2020	June 3, 2021	=	◇	◇	◇
2019	June 10, 2020	=	◇	◇	◇
2018	June 12, 2019	=	◇	◇	◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Gilmore O'Neill (President and Chief Executive Officer), FY2025 total compensation $2,353,655 (base salary $686,574) [exec_comp, SEC accession 0001650664-26-000037, filed 2026-04-28]

See a complete sample report

What this page does not include

Everything above is a fact Editas Medicine disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Editas Medicine sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $500

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

203 figures on this page: 195 cited to the filing that reported them, 8 calculated from figures it prints.

195 cited to the filing

8 calculated from the filing

Documents cited

8-K, filed June 18, 2026
0001650664-26-000063
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 28, 2026
0001650664-26-000037
2025 Summary Compensation Table · Director Compensation · Outstanding Equity Awards at Fiscal Year-End · TABLE OF CONTENTS EXECUTIVE COMPENSATION
8-K, filed June 2, 2025
0001650664-25-000086
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 15, 2025
0001650664-25-000058
2024 Summary Compensation Table
8-K, filed May 31, 2024
0001650664-24-000050
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 16, 2024
0001650664-24-000025
Summary Compensation Table
8-K, filed June 5, 2023
0001558370-23-010811
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 13, 2022
0001558370-22-009970
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 8, 2021
0001558370-21-008121
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 15, 2020
0001558370-20-007536
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 14, 2019
0001558370-19-005722
Item 5.07 Submission of Matters to a Vote of Security Holders

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Editas Medicine executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/EDIT (accessed 2026).

Short form: data: Velarion

The Editas Medicine brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

11 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/EDIT/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Editas Medicine executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Editas Medicine and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life Sciences CEO pay ratio — Biopharma & Life Sciences Say-on-pay support — Biopharma & Life Sciences

Peers Editas Medicine discloses

The companies named in EDIT's own disclosed peer group.

Adicet Bio, Inc.Cabaletta Bio, Inc.Caribou Biosciences, Inc.Fate Therapeutics, Inc.Lexeo Therapeutics, Inc.Lyell Immunopharma, Inc.Neurogene Inc.Nkarta, Inc.Prime Medicine, Inc.Solid Biosciences Inc.Tenaya Therapeutics, Inc.TScan Therapeutics, Inc.Voyager, Inc.

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}